BLIS Technologies Posts 42% Revenue Surge and Returns to Profit in 1Q27
BLIS Technologies has kicked off FY27 with a 42% revenue increase and a return to EBITDA profitability, driven by strong B2B growth in Asia Pacific and China.
- 42% revenue growth to NZD 5.1 million in 1Q27
- EBITDA swings to NZD 1.1 million profit from prior loss
- B2B revenue up 67%, led by Asia Pacific and China
- B2C revenue rises modestly by 4%
- FY27 revenue growth forecast maintained at 10%-15%
Strong Early Momentum in FY27
BLIS Technologies (NZX:BLT) has delivered a robust start to its 2027 financial year, reporting a 42% jump in revenue to NZD 5.1 million for the first quarter ended 30 June 2026. This surge marks a significant turnaround from the same period last year, when revenue was NZD 3.6 million. More notably, the company swung from a NZD 0.2 million EBITDA loss in 1Q26 to a NZD 1.1 million profit in 1Q27, signaling improved operational leverage.
B2B Sales Fuel Growth, Asia Pacific and China Lead
The standout driver behind BLIS’s growth was its business-to-business (B2B) segment, which expanded 67% year-on-year. This was propelled primarily by ingredient sales growth across Asia Pacific and strong royalty and private label contributions in China. However, the company noted some softness in European ingredient sales, partially offsetting gains. Meanwhile, the business-to-consumer (B2C) side saw more modest progress, with revenue edging up 4% compared to 1Q26.
Maintaining a Cautious but Positive Outlook
CEO Scott Johnson described the quarter as "exceptional," highlighting record revenue and EBITDA. Despite the strong start, he cautioned against extrapolating first-quarter results to the full year but reaffirmed the company’s existing FY27 revenue growth guidance of 10% to 15%. This outlook aligns with BLIS’s recent trajectory, which included a 16% revenue increase in FY26 and resolution of a key intellectual property dispute, setting a foundation for sustained expansion in strategic markets.
Global Reach and Product Focus
BLIS continues to leverage its advanced probiotic strains targeting health areas beyond the gut, including throat health, immune support, and oral care. Its products are distributed across New Zealand, Asia, Europe, and the USA, with Asia Pacific and China emerging as critical growth engines. The company’s ability to convert innovation into commercial success remains central to its strategy.
Bottom Line?
BLIS’s strong Q1 performance confirms momentum but leaves open questions about sustaining growth amid regional variability and competitive pressures.
Questions in the middle?
- Can BLIS sustain its B2B momentum, especially in China and Asia Pacific, throughout FY27?
- What impact will weaker European ingredient sales have on full-year results?
- How will BLIS’s innovation pipeline and IP position influence its competitive edge going forward?
